NEWS RELEASE

Evolus to Participate in Upcoming Investor Conferences in New York and London

2026-10-28

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- **Evolus, Inc.** (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor conferences in New York and London:

- The Stifel Healthcare Conference, where management will participate in a fireside chat and host investor meetings on Wednesday, November 11, 2026, in New York City. The fireside chat is scheduled for 2:00 PM ET.
- The Jefferies Global Healthcare Conference, where management will host investor meetings on November 16 th – 17 th, 2026, in London, United Kingdom.

The live webcast of the Stifel Healthcare Conference fireside chat will be accessible through the Investor Relations section of the Evolus website **here**. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at **www.evolus.com**, and follow us on **LinkedIn**, **X**, **Instagram** or **Facebook**.

Jeuveau®, Nuceiva®, and Evolysse® are registered trademarks of Evolus, Inc.

Profhilo® is a registered trademark of IBSA Institut Biochimique SA.

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: **ir@evolus.com**

Media:

Email: **media@evolus.com**

Source: Evolus